Pulmonary sporotrichosis in Oklahoma in susceptibilities in vitro.

Abstract

Six cases of pulmonary sporotichosis were observed in 2 institutions in Oklahoma City, Okla. Three of the patients were treated with iodides with or without surgery. Although one patient required a second course of iodides, the patients have remained well after at least 34 months of follow-up. Three patients treated with amphotericin B, single course as well as multiple courses, and other antifungal agents (hydroxystilbamidine and miconazole) have all relapsed. These cases and a reviewed of more than 40 cases of pulmonary sporotrichosis susceptibilities of Sporothrix schenckii that we observed in vitro suggest that amphotericin B is not an effective agent for the treatment of pulmonary sporotrichosis. It is our opinion that the treatment of choice for pulmonary sporotrichosis is a supersaturated solution of potassium iodide. If the patient is allergic to the medication or fails to respond, then a combination of amphotericin B plus flucytosine may be tried.

• Authors: J A Mohr, W Griffiths, H Long
• Journal: The American review of respiratory disease (Am Rev Respir Dis) Vol. 119 Issue 6 Pg. 961-4 (Jun 1979) ISSN: 0003-0805 [Print] United States
• PMID: 582240 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Antifungal Agents
• Stilbamidines
• Potassium Iodide
• Miconazole
• Amphotericin B

Topics

• Adult
• Amphotericin B (therapeutic use)
• Antifungal Agents (pharmacology, therapeutic use)
• Female
• Follow-Up Studies
• Humans
• In Vitro Techniques
• Lung Diseases, Fungal (drug therapy, epidemiology)
• Male
• Miconazole (therapeutic use)
• Middle Aged
• Oklahoma
• Potassium Iodide (therapeutic use)
• Sporothrix (drug effects)
• Sporotrichosis (drug therapy, epidemiology)
• Stilbamidines (therapeutic use)